While comprehensive evaluation of the efficacy of ICI in NSCLC post-TKI treatment resistance was not readily available in the literature, a few have investigated outcomes in patients receiving EGFR-targeted TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.